key: cord-0965750-unq4ufmc
authors: Woldemeskel, Bezawit A.; Garliss, Caroline C.; Aytenfisu, Tihitina Y.; Johnston, Trevor S.; Cox, Andrea L.; Karaba, Andrew H.; Blankson, Joel N.
title: Discordant antibody and T cell responses to the SARS-CoV-2 Omicron variant in COVID-19 mRNA vaccine recipient
date: 2022-04-19
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac305
sha: ac8c6ed684777a8d01351270fa97dd05b43ffc6f
doc_id: 965750
cord_uid: unq4ufmc

We compared antibody and T cell responses against the SARS-CoV-2 vaccine strain spike protein to responses against the Omicron variant in 15 mRNA vaccine recipients. While these individuals had significantly lower levels of antibodies that inhibited Omicron spike protein binding to ACE2, there was no difference in T cell responses.

The Omicron variant was first reported in November 2021 by scientists in South Africa. The variant 2 contains more than 50 mutations, including 33 in the spike protein, and studies show that this results in 3 evasion of vaccine-elicited neutralizing antibodies [1] . However, less is known about how these 4 mutations impact the T cell response to the virus. We compared antibody and T cell responses to the 5 vaccine strain and Omicron variant spike proteins in 15 mRNA vaccine recipients (VRs). Our data may 6 partially explain the clinical outcomes seen in VRs with breakthrough Omicron variant infection. 7

We obtained blood from 15 VRs (7 men, 8 women) after informed consent was obtained. The study was 9 approved by the Johns Hopkins University institutional review board. Eleven VRs received the Pfizer-10 BioNTech (BNT162b2) vaccine with a homologous booster, one VR received BNT162b2 followed by the 11

Moderna (mRNA-1273) vaccine, and one VR received mRNA-1273 followed by a homologous booster 12 vaccine. The other two VRs received two doses of BNT162b2 without a booster vaccine. 13

Twelve of the VRs were 21-30 years old, one was 41 to 50 years old and two were 51 to 60 years old. 14 Informed consent was obtained from all study participants. Peripheral blood mononuclear cells (PBMCs) 15 were isolated from whole blood using Ficoll centrifugation. mRNA for the nucleocapsid protein is not 16 included in vaccines so natural infection was ruled out by screening for T cell responses to a pool of 57 17 nucleocapsid peptides at a concentration of 10 ug/ml (BEI, Manassas, VA). To measure the ability of 18 participant plasma to inhibit ACE2 binding to spike proteins from the vaccine strain and multiple VOCs, 19

we used the Meso Scale Discoveries pseudoneutralization/ACE2 inhibition assay (Rockville, Maryland, 20 USA). The percent inhibition of ACE2 binding measured with this assay correlates well with the results of 21 culture-based neutralization assays [2] . The assay was performed with plasma diluted at 1:100 as 22 previously described [2] . We determined cellular immunity to the SARS-CoV-2 spike protein by 23

performing an interferon-γ (IFN-γ) Elispot assay with unfractionated PBMCs as previously described [3] . 1

The assay was also performed with CD8+ T cell-depleted PBMCs to determine the relative contribution 2 of CD4+ T cells and CD8+ T cells to the total T cell response. CD8+ T cells were removed by positive 3 selection with CD8 MicroBeads (Miltenyi Biotec, Gaithersburg Maryland). This process typically removes 4 > 90% of CD8+ T cells as determined by flow cytometry. To compare recognition of spike proteins from 5 the vaccine strain and the Omicron variant, we stimulated PBMCs with overlapping spike peptide pools 6 from both viruses at a concentration of 1 μg/mL (JPT, Berlin, Germany). Both spike peptide pools were 7 made up of 315 peptides that were mostly 15 amino acids long with an overlap of 11 amino acids. 8

Statistical comparisons were done using GraphPad Prism 9.2.0. Comparisons were made with One-way 9 ANOVA with Geisser-Greenhouse correction Dunnet's multiple comparison test was done, with 10 individual variances computed for each comparison. P value < 0.05 was considered significant. 11

Results 12 VR plasma contained significantly lower levels of antibodies that inhibited the binding of ACE2 to spike 13 proteins from the Alpha, Beta, Delta, and Omicron variants than to the vaccine strain spike protein. 14 ACE2 binding to the Omicron spike protein was least inhibited by the VR plasma. ( Figure 1A) . 15

In contrast, the VRs made robust T cell responses to peptide pools from both vaccine strain and Omicron 16 spike proteins ( Figure 1B) . Interestingly, depletion of CD8+ T cells did not result in a significant decrease 17 in the total T cell response to both sets of spike peptides, implying that CD4+ T cells were the major 18 producers of IFN-g in the assay ( Figure 1C ). There was a strong correlation between T cell responses to 19 spike peptides from the vaccine strain and from the omicron variant, with both total ( Figure 1D ) and 20 CD8 depleted T cells ( Figure 1E epitopes. This lack of significant T cell escape by Omicron and prior variants is most likely due to the fact 14 that mRNA vaccines induce broad T cell responses that target many different epitopes in the spike 15 protein [3, 5, 9, 12] . These broad mRNA vaccine-elicited T cell responses will likely be effective against 16 future variants of concern that evade antibody responses. 17

Acknowledgements: We thank the study participants as well as Christopher Thoburn and Jennifer Gizzi 19 of the Bloomberg Flow Cytometry and Immunology Core. 

Neutralization of SARS-CoV-2 Omicron variant by sera from

A third dose of SARS-CoV-2 vaccine increases neutralizing 4 antibodies against variants of concern in solid organ transplant recipients

Epub ahead of print

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell 7 responses that recognize SARS-CoV-2 variants and HCoV-NL63

Minimal Crossover between Mutations Associated with

Omicron Variant of SARS-CoV-2 and CD8+ T-Cell Epitopes Identified in COVID-19 Convalescent 11 Individuals. mBio

Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T 13 cell reactivity in infected or vaccinated individuals

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron 15 variant

T cell responses to SARS-CoV-2 spike cross-recognize

Vaccines Elicit Highly Conserved Cellular Immunity to

SARS-CoV-2 Omicron

SARS-CoV-2 vaccination induces immunological T cell memory 21 able to cross-recognize variants from Alpha to Omicron